minocycline has been researched along with Dermatitis--Seborrheic* in 2 studies
1 trial(s) available for minocycline and Dermatitis--Seborrheic
Article | Year |
---|---|
Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris.
In addition to tetracyclines, zinc may constitute an alternative treatment in inflammatory lesions of acne.. To evaluate the place of zinc gluconate in relation to antibiotics in the treatment of acne vulgaris.. Zinc was compared to minocycline in a multicenter randomized double-blind trial. 332 patients received either 30 mg elemental zinc or 100 mg minocycline over 3 months. The primary endpoint was defined as the percentage of the clinical success rate on day 90 (i.e. more than 2/3 decrease in inflammatory lesions, i.e. papules and pustules).. This clinical success rate was 31.2% for zinc and 63.4% for minocycline. Minocycline nevertheless showed a 9% superiority in action at 1 month and one of 17% at 3 months, with respect to the mean change in lesion count. Regarding safety, the majority of the adverse effects of zinc gluconate and of minocycline concerned the gastrointestinal system and were moderate (5 dropouts with zinc gluconate and 4 with minocycline).. Minocycline and zinc gluconate are both effective in the treatment of inflammatory acne, but minocycline has a superior effect evaluated to be 17% in our study. Topics: Abdominal Pain; Acne Vulgaris; Adolescent; Adult; Anti-Bacterial Agents; Arthralgia; Dermatitis, Seborrheic; Double-Blind Method; Female; Gluconates; Humans; Hypersensitivity; Male; Minocycline; Nausea; Patient Compliance; Patient Dropouts; Patient Satisfaction; Skin; Treatment Outcome; Urticaria; Vomiting; Zinc | 2001 |
1 other study(ies) available for minocycline and Dermatitis--Seborrheic
Article | Year |
---|---|
Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis.
To assess the effect of minocycline on the ocular flora in patients with acne rosacea or blepharitis.. A total of ten patients were enrolled in this prospective study, with six patients diagnosed with acne rosacea with concomitant meibomianitis, two patients with acne rosacea without concomitant ocular involvement, and two patients with seborrheic blepharitis. The eyelids and conjunctiva of both eyes were cultured before the initiation of systemic minocycline therapy, after 3 months of active therapy, and 3 months after the discontinuation of therapy. Isolated bacteria were identified and quantified, and antibiotic susceptibility was determined.. The colony-forming units (CFU) isolated from the eyelids significantly decreased after a 3-month treatment with minocycline (P = 0.0013). The CFU significantly increased to approach that of the baseline with the discontinuation of minocycline (P = 0.0275). The most common isolated bacteria, including coagulase-negative Staphylococcus (CNS), Staphylococcus aureus (S. aureus), and Propionibacterium acne (P. acne), except for corynebacterium, had a significant decrease in bacterial count with minocycline therapy compared with baseline (P < 0.05). There was a trend in the decrease of bacterial CFU isolated from the conjunctiva with minocycline therapy, although this was not statistically significant (P = 0.1955). Four of the ten patients carried tetracycline-resistant CNS strains, but none of the S. aureus or P. acne isolated at baseline was resistant to tetracycline. All six patients with acne rosacea and concomitant meibomianitis had marked clinical improvement.. Minocycline effectively decreased eyelid bacterial flora in patients with acne rosacea or blepharitis. One of the mechanisms of newer generation tetracycline analogues may be a decrease or elimination of bacterial flora from the eyelids. Topics: Anti-Bacterial Agents; Bacteria; Blepharitis; Colony-Forming Units Assay; Dermatitis, Seborrheic; Drug Administration Schedule; Eye; Humans; Minocycline; Prospective Studies; Rosacea; Stem Cells | 2003 |